Singapur - Englisch - HSA (Health Sciences Authority)

pfizer private limited - desferrioxamine mesylate - injection, powder, for solution - 500 mg/vial - desferrioxamine mesylate 500 mg/vial

Kanada - Englisch - Health Canada

bracco imaging canada - sulfur hexafluoride - powder for suspension - 8mcl - sulfur hexafluoride 8mcl - other diagnostic agents

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - desferrioxamine mesilate, quantity: 2 g - injection, powder for - excipient ingredients: - chronic iron overload. desferrioxamine mesylate is used to promote iron excretion in patients with iron overload as a result of multiple blood transfusions frequently used in the treatment of some chronic anaemias and thalassaemia. long-term therapy with desferrioxamine mesylate slows accumulation of hepatic iron and retards or eliminates progression of hepatic fibrosis. patients under the age of 3 years with small degree of iron overload have relatively poor iron mobilisation with desferrioxamine mesylate. the drug is not normally given to such patients unless significant iron mobilisation of 1mg or more of iron per day can be demonstrated. desferrioxamine mesylate is not indicated for the treatment of primary haemochromatosis as phlebotomy is the method of choice for removing excess iron in this disorder. acute iron poisoning: desferrioxamine mesylate is an adjunct to, and not a substitute for, standard measures used in treating acute iron poisoning, which may include induction of emesis, gastric lavage, suction and maintenance of a clear airway, control of shock with intravenous fluids, blood, oxygen and vasopressor and correction of acidosis.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - desferrioxamine mesilate, quantity: 500 mg - injection, powder for - excipient ingredients: - chronic iron overload. desferrioxamine mesylate is used to promote iron excretion in patients with iron overload as a result of multiple blood transfusions frequently used in the treatment of some chronic anaemias and thalassaemia. long-term therapy with desferrioxamine mesylate slows accumulation of hepatic iron and retards or eliminates progression of hepatic fibrosis. patients under the age of 3 years with small degree of iron overload have relatively poor iron mobilisation with desferrioxamine mesylate. the drug is not normally given to such patients unless significant iron mobilisation of 1mg or more of iron per day can be demonstrated. desferrioxamine mesylate is not indicated for the treatment of primary haemochromatosis as phlebotomy is the method of choice for removing excess iron in this disorder. acute iron poisoning: desferrioxamine mesylate is an adjunct to, and not a substitute for, standard measures used in treating acute iron poisoning, which may include induction of emesis, gastric lavage, suction and maintenance of a clear airway, control of shock with intravenous fluids, blood, oxygen and vasopressor and correction of acidosis.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

aurobindo pharma australia pty ltd - carvedilol -

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - carvedilol -

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

scentia pharmaceuticals pty ltd - carvedilol -

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - carvedilol -

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

actavis pty ltd - carvedilol -

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

aurobindo pharma australia pty ltd - carvedilol -